Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging...